May 12, 2021
Video
The director at AbbVie discussed the timeline for when a regulatory decision may come for migraine treatment atogepant, and whether additional trials are necessary.
May 04, 2021
Video
The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.
April 22, 2021
Video
The director at AbbVie discussed a number of abstracts presented at AAN 2021 involving atogepant and its phase 3 ADVANCE study.
NeurologyLive® Brain Games: May 22, 2022
New Research Highlights Reasons, Risk Factors, and Consequences for Self-Discontinuation of Antiseizure Medication in Newly Diagnosed Epilepsy
New Drug Application Submitted for Continuous Subcutaneous Carbidopa/Levodopa Formulation
Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted